{
    "id": "correct_subsidiary_00047_1",
    "rank": 54,
    "data": {
        "url": "https://www.mdedge.com/dermatology/article/11123/emerging-insights-and-new-therapeutic-opportunities-acne-and-atopic",
        "read_more_link": "",
        "language": "en",
        "title": "Emerging Insights and New Therapeutic Opportunities: Acne and Atopic Dermatitis",
        "top_image": "https://cdn.mdedge.com/files/s3fs-public/styles/teaser_opengraph/public/Image/July-2016/wyxs27v8_sanews_supplement41_0.jpg",
        "meta_img": "https://cdn.mdedge.com/files/s3fs-public/styles/teaser_opengraph/public/Image/July-2016/wyxs27v8_sanews_supplement41_0.jpg",
        "images": [
            "https://www.facebook.com/tr?id=405762156989601&ev=PageView&noscript=1",
            "https://www.mdedge.com/sites/all/themes/custom/medstat_aurora/img/logo-mdedge.png",
            "https://www.mdedge.com/sites/all/themes/custom/medstat_aurora/img/search_icon.png",
            "https://www.mdedge.com/sites/all/themes/custom/medstat_aurora/img/logo-mdedge@2x.png",
            "https://www.mdedge.com/sites/all/themes/custom/medstat_aurora/img/logo-mdedge@2x.png",
            "https://www.mdedge.com/sites/all/themes/custom/medstat_aurora/img/search_icon.png",
            "https://www.mdedge.com/sites/all/themes/custom/medstat_aurora/img/consolidated-logos/medstat_san/logo.png",
            "https://cdn.mdedge.com/files/s3fs-public/Image/September-2017/wyxs27v8_sanews_supplement41.jpg",
            "https://cdn.mdedge.com/files/s3fs-public/Image/September-2017/wyxs27v8_sanews_supplement41.jpg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2010-02-22T15:46:21-05:00",
        "summary": "",
        "meta_description": "A supplement to Skin &amp; Allergy News.Supported by Stiefel.The articles in this supplement are based on presentations",
        "meta_lang": "en",
        "meta_favicon": "https://www.mdedge.com/misc/favicon.ico",
        "meta_site_name": "",
        "canonical_link": "https://www.mdedge.com/dermatology/article/11123/emerging-insights-and-new-therapeutic-opportunities-acne-and-atopic",
        "text": "A supplement to Skin & Allergy News.\n\nSupported by Stiefel.\n\nThe articles in this supplement are based on presentations made during Skin Disease Education Foundation's 30th Annual Hawaii Dermatology Seminar, held February 13, 2006, in Kauai, Hawaii.\n\n•Topics\n\n•Faculty/Faculty Disclosure Statement\n\n•Target Audience\n\nTo view the supplement, click the image above.\n\nTopics\n\n• Introduction\n\n• The Importance of Vehicle and Skin Barrier Function in Acne Vulgaris\n\n• Combination Therapy Considerations in Acne Vulgaris\n\n• Evolving Therapy in Atopic Dermatitis\n\n• Nonsteroidal Treatment of Atopic Dermatitis\n\nFaculty/Faculty Disclosure Statement\n\nEmil A. Tanghetti, MD, Chair\n\nClinical Professor of Dermatology\n\nUniversity of California, Davis School of Medicine\n\nMedical Director\n\nCenter for Dermatology and Laser Surgery\n\nSacramento\n\nDr. Tanghetti has received funding for clinical grants from and is a consultant to Allergan Inc., and Stiefel Laboratories, Inc.\n\nLeon Kircik, MD\n\nClinical Associate Professor\n\nDivision of Dermatology\n\nIndiana University\n\nIndianapolis\n\nMedical Director\n\nPhysicians Skin Care, PLLC\n\nLouisville, Ky.\n\nDr. Kircik has received funding as an investigator, consultant, advisor, or speaker from Abbott Laboratories, Allergan Inc., Amgen, Inc., Astellas Pharma US, Inc., Berlex Inc., Biogen Idec Inc., Centocor, Inc., Connetics Corporation, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech Inc., GlaxoSmithKline, HealthPoint Ltd., Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceutical Corporation, QLT Inc., SkinMedica, Stiefel Laboratories, Inc., 3M Pharmaceuticals, Valeant Pharmaceuticals International, and Warner-Chilcott, PLC. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: clindamycin 1% benzoyl peroxide 5% gel (Duac Topical Gel) for acne.\n\nLawrence F. Eichenfield, MD\n\nProfessor of Pediatrics and Medicine (Dermatology)\n\nUniversity of California, San Diego, School of Medicine\n\nChildren's Hospital\n\nSan Diego\n\nDr. Eichenfield has received clinical grants from Astellas Pharma US, Inc., Connetics Corporation, Dermik Laboratories, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., GlaxoSmithKline, Hill Dermacueticals, Inc., and Novartis Pharmaceuticals Corporation. He is also a consultant to Connetics and Novartis. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis, MAS063D (Atopiclair) for atopic dermatitis, and a probiotic, Lactobacillus fermentum, for atopic dermatitis.\n\nJames Turner, MD, PhD\n\nClinical Professor\n\nDivision of Dermatology\n\nDepartment of Medicine\n\nUniversity of Tennessee\n\nMemphis\n\nDr. Turner is a consultant to Stiefel Laboratories, Inc. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis and clindamycin 1% benzoyl peroxide 5% gel.\n\nTarget Audience\n\nThis activity is intended for healthcare professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with acne vulgaris or atopic dermatitis."
    }
}